Economic and cost-effectiveness aspects of vaccines in combating antibiotic resistance

Antimicrobial resistance (AMR) is a global public health threat causing substantial morbidity and mortality as well as significant economic costs. Vaccines can contribute to combating antimicrobial resistance by reducing the incidence of resistant disease cases and lowering overall antibiotic use. G...

Full description

Saved in:
Bibliographic Details
Published in:Human vaccines & immunotherapeutics 2023-12, Vol.19 (1), p.2215149-2215149
Main Authors: Yemeke, Tatenda, Chen, Hui-Han, Ozawa, Sachiko
Format: Article
Language:English
Subjects:
AMR
Anti-Bacterial Agents - pharmacology
Anti-Bacterial Agents - therapeutic use
antimicrobial resistance
Cost-Benefit Analysis
cost-effectiveness
Drug Resistance, Microbial
economics
Humans
Pneumococcal Infections - epidemiology
Pneumococcal Vaccines
Public Health – Review
Review
Vaccination
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Antimicrobial resistance (AMR) is a global public health threat causing substantial morbidity and mortality as well as significant economic costs. Vaccines can contribute to combating antimicrobial resistance by reducing the incidence of resistant disease cases and lowering overall antibiotic use. Greater utilization and investments in vaccines as a tool for combating AMR might be hampered by limited economic evidence demonstrating the AMR-related value of vaccines. We reviewed the existing literature to assess the state of evidence. We found two modeling studies that provided estimates of AMR-related costs averted by pneumococcal vaccination and a few cost-effectiveness studies that exclusively focused on serotype replacement effects on overall vaccine cost-effectiveness. We did not find any cost-effectiveness studies that directly examined the cost-effectiveness of vaccines in slowing the development of AMR. Further evidence on the cost-effectiveness and economic value of vaccines in controlling AMR can help inform resource allocation decisions and guide development priorities.
ISSN:2164-5515
2164-554X
DOI:10.1080/21645515.2023.2215149